SCLX Scilex Holding Company

NEUTRAL Impact: 4/10 PRESS-RELEASE
Horizon days Filed Jun 4, 2026 Processed 8d 20h ago Wire GlobeNewswire
Press release: dividend
Latest settled — T+1d
SCLX ▼ -7.65% at T+1d
NEUTRAL call ✗ call lost -7.65% · α vs SPY -5.05% · entry $7.58 → $7.00
Next anchor: T+5d due yesterday
Currently $8.50 · +12.14% from $7.58 entry
Entry anchored
Jun 3, 03:58 PM ET
via Databento tick
T+1d
-7.65%
call -7.65% · α -5.05%
$7.00
settled 8d ago
T+5d
call — · α —
due yesterday
T+20d
call — · α —
in 20d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Scilex announced a June 15, 2026 payment date for its previously declared dividend of Semnur Pharmaceuticals (OTC: SMNR) common stock, distributing approximately 14 million shares to holders of record as of June 1, 2026. The dividend is subject to board revocation and provides a direct distribution of a key subsidiary's stock to Scilex shareholders.

Actionable Insight

The dividend provides a direct stake in Semnur, which holds the SEMDEXA (SP-102) asset. Monitor for any board revocation or changes to the payment date. The ex-dividend date set by Nasdaq will determine the trading adjustment for SCLX shares.

Key Facts

  • Payment date set for June 15, 2026; record date is June 1, 2026.
  • One share of Semnur common stock per share of Scilex common stock held.
  • Approximately 14 million Semnur shares to be distributed out of 186 million beneficially owned by Scilex.
  • Dividend is conditioned on board not revoking it prior to payment date.
  • Board retains right to change record date and payment date at any time.

Financial Impact

Distribution of ~14 million shares of Semnur common stock; Scilex retains ~172 million shares post-dividend.

share countownership structure

Risk Factors

  • Board may revoke or modify the dividend at any time before payment.
  • Semnur (OTC: SMNR) may have limited liquidity, affecting the value of distributed shares.
  • Scilex retains majority ownership of Semnur, so the dividend does not fully separate the entities.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306806
8 reports for SCLX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SCLX — sortable, filterable
Type Now
Jun 12, 2026
today
Press Release
NEUTRAL ★ 2/10
$8.75 awaiting T+1awaiting T+1$8.50 (−2.86%)
Jun 12, 2026
1d ago
EFFECT
BEARISH ★ 6/10
$8.75 awaiting T+1awaiting T+1$8.50 (+2.86%)
Jun 11, 2026
1d ago
Institutional Cluster
NEUTRAL ★ 2/10
$8.53 awaiting T+1awaiting T+1$8.50 (−0.35%)
Jun 4, 2026
8d ago
Press Release
NEUTRAL ★ 4/10
$7.58 $7.00▼ −7.65%▼ −5.05%$8.50 (+12.14%)
May 5, 2026
5w ago
Press Release
BULLISH ★ 8/10
$10.73 $9.50▼ −11.46%▼ −12.85%$8.50 (−20.78%)
May 4, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$11.15 $10.73▼ −3.77%▼ −4.56%$8.50 (−23.77%)
Apr 17, 2026
8w ago
Insider Cluster
MIXED ★ 6/10
$6.90 $6.95▲ +0.65%▲ +0.84%$8.50 (+23.19%)
Mar 13, 2026
13w ago
8-K
BEARISH ★ 8/10
$8.28 $8.43▼ −1.81%▼ −0.79%$8.50 (−2.66%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (52h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access